Ireland's Trinity Biotech Q1 revenue rises on HIV test sales

Trinity Biotech

16/06/2026 14:22

Overview
Ireland diagnostics firm's Q1 2026 revenue rose 43% yr/yr, driven by rapid HIV and haemoglobin test sales
Gross margin for Q1 improved to 35.4% from 25.2%, supported by transformation plan changes
Company received purchase orders for over 2 mln rapid HIV tests, reinforcing strong demand outlook

Outlook
Company expects new HIV test orders to support 2026 revenue and profitability targets
Trinity Biotech sees renewed, broad-based demand for rapid HIV diagnostics in global markets
Company expects commercial scale-up of outsourced UniGold HIV production to be in place Q3 2026

Result Drivers
RAPID HIV SALES - Higher TrinScreen HIV sales and new orders contributed to revenue growth
OPERATING STRUCTURE CHANGES - Gross margin improvement supported by changes under Comprehensive Transformation Plan
OUTSOURCED MANUFACTURING - Scale-up of outsourced UniGold HIV production expected to further improve margins and cashflow

Company press release: ID:nGNX2sR3yT

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
 
$10.80 mln
 
Q1 Gross Margin
 
35.40%
 
Q1 Gross Profit
 
$3.80 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)